200028:SZSEChina National Accord Medicines Corporation Ltd. Analysis

China National Accord Medicines (200028.SZ) trades at HK$13.79, comfortably above its 20‑day SMA (13.87) but below the 50‑day SMA (13.74) and 200‑day SMA (13.38), indicating a short‑term bullish bias that is tempered by a bearish MACD histogram and a price perched near the technical resistance of HK$14.09. The stock is priced at a forward PE of 4.55 and a trailing PE of 12.65, well under the industry average PE of 26.7, while its price‑to‑book is only 0.37, suggesting a deep valuation gap. DCF analysis projects a fair value of around HK$30, more than double the current price.
Fundamentally, the company faces challenges: revenue fell 1.9% YoY, profit margins are thin (net margin 0.73%), and ROE is a modest 0.7%, prompting a recent Citi downgrade to “sell.” Nevertheless, the firm generates solid free cash flow, supports a 2.9% dividend yield with a 38% payout ratio, and benefits from a low beta of 0.15 and moderate 30‑day volatility (9.6%), which together mitigate broader market risk.